Clinical trial · Interventional
CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients
Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits. This project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts . The personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Risk | — | UNRESOLVED | — |
| Management | — | UNRESOLVED | — |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Personalized Discharge Letter | Behavioral | — | UNRESOLVED |
| Personalized Discharge Letter + IntelliStudio | Behavioral | — | UNRESOLVED |
| Verbal information only | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Group A: Standard of Care
- description
- Verbal information only.
- interventionNames
- Behavioral: Verbal information only
- type
- EXPERIMENTAL
- label
- Group B: Personalized Discharge Letter
- description
- Tailored written information based on individual risk profile, skin type and consultation findings.
- interventionNames
- Behavioral: Personalized Discharge Letter
- type
- EXPERIMENTAL
- label
- Group C: Personalized Discharge Letter + Digital Visual Support (IntelliStudio)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Low-risk skin cancer patients: 1. Negative personal history for melanoma 2. Less than 100 naevi 3. Less than 5 clinically atypical naevi 4. Maximum 1 BCC in history 5. Maximum 1 SCC, and at least 5 years ago 6. AK: treated and controlled with clinical response 7. M Bowen: treated and controlled with clinical response * Adult subjects (between 18 years of age and 80 years) at time of enrolment Exclusion Criteria: * Presence of dermatological lesions requiring immediate treatment at the time of consultation. * History of solid organ transplantation (Organ Transplant Recipient, OTR). * Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes). * Failure to meet one or more of the inclusion criteria. * Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier). * Participation in another interventional clinical trial that may interfere with the outcomes of this study.
References
Publications (0)
Data not yet available